Back to news

Nasus Pharma Presents Data at ACAAI 2026 Demonstrating NS002 Reached the Therapeutic Epinephrine Threshold Faster Than an Autoinjector After Repeat Dosing and Under Severe Nasal Congestion

Globe Newswire•17/11/2026•08:00 ET
0

Key Highlights

  • ➤NS002 reached the 100 pg/mL therapeutic threshold faster than an autoinjector after single dosing
  • ➤NS002 reached the 100 pg/mL threshold faster than an autoinjector after repeat dosing
  • ➤NS002 potentially outperformed an autoinjector under severe nasal congestion
  • ➤Nasus Pharma plans to initiate the NS002 pivotal study before end-2026
  • ➤Topline NS002 pivotal-study data are expected in first quarter 2027

Expert Statements

Brendan O’Grady, Chief Executive Officer of Nasus Pharma

“We believe the data presented to the allergy and immunology community at ACAAI represent an important validation of NS002 and the potential of our Nasax(®) platform”

Brendan O’Grady, Chief Executive Officer of Nasus Pharma

“We are encouraged by these results, and confident in the program as we prepare to initiate the NS002 pivotal study before the end of 2026 and a topline data readout in the first quarter of 2027.”

TEL AVIV, Israel, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced highlights of positive data presented at the American College of Allergy, Asthma and Immunology (“ACAAI”) 2026 Annual Scientific Meeting, held November 12-16 in Phoenix, Arizona. Results from the Company’s NP007 trial, a Phase 2 study of NS002, its investigational intranasal epinephrine powder for the treatment of anaphylaxis, were selected for oral presentation in the “Distinguish Industry and Late Breaking Abstracts” session and as posters during the conference. Additional survey results of U.S. allergists on the importance of speed of onset in anaphylaxis were also presented.

The data presented at the ACAAI highlighted results from the NP007 study, which demonstrated that NS002 achieved faster time to therapeutic threshold as compared to an autoinjector. NS002 reached the 100 pg/mL threshold sooner than the autoinjector after both single and repeat dosing. Potential superiority was also demonstrated against the autoinjector in conditions of severe nasal congestion. No serious adverse events were observed. Additional survey data of U.S. allergists showed that prescribers emphasize speed of onset and the proportion of patients reaching the therapeutic level within the first minutes as meaningful differences when considering therapeutic options.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in